A rare case of hypodysfibrinogenemia in patient without hematomesenchymal dysplasia: 616.151.5-007.17-053.2/.7-616-053.2

Abstract

Summary. Fibrinogen and collagen are the most important intercellular matrix proteins that directly effect on the differentiation of mesenchymal stem cells and osteogenesis. In addition, there are non-classical cases of this syndrome that require indepth study of pathogenesis and optimal disease correction. We examined literature data by keywords in databases PubMed, UpToDate, BMJ. We presented a review of current scientific data and observation results of a rare clinical case in a patient with hypodysfibrinogenemia without hematomesenchymal dysplasia with manifestations of aseptic necrosis of femoral heads. Conclusions: In general, various aspects of clinical and biochemical pathogenesis of fibrinogen abnormalities are currently studied in detail, but there are “white spots” in the study of sophisticated pathogenetic mechanisms at the molecular genetic level, namely protein catabolism, the reaction of separate synthesis of individual fibrinogen polypeptide chains in different tissues. Unresolved is the question of applicability of hemostatic corrective drugs in the absence of expressed thrombotic and hemorrhagic manifestations.

References

1. Barkagan Z.S., Momot A.P. Diagnosis and controlled therapy of hemostasis disorders. Moscow: N’yudiamed, 2008. 290 p. (In Russ.).
2. Sidor N.V., Momot A.P. Factor XIII. Structure, function, determination methods, role in human pathology. Tromboz, gemostaz i reologiya. 2003;(1):10–21. (In Russ.).
3. Undas A., Casini A. Congenital structural and functional fibrinogen disorders: a primer for internists. Pol Arch Intern Med. 2019;129(12):913–20. DOI: 10.20452/pamw.15082.
4. Noori A., Ashrafi S.J., Vaez-Ghaemi R. et al. A review of fibrin and fibrin composites for bone tissue engineering. Int J Nanomedicine. 2017;12:4937–61. DOI: 10.2147/IJN.S124671.
5. Menache D., Boivin P. Acquired factor X deficiency in a patient with primary amyloidosis. Injection of A B.S.C. fraction. Bibl Haematol. 1964;19:185–91.
6. Zhang X., Zhang C., Wang B.et al. Congenital fibrinogen disorders with repeated thrombosis. J Thromb Thrombolysis. 2019. DOI: 10.1007/s11239–019–01958-y.
7. Besser M.W., MacDonald S.G. Acquired hypofibrinogenemia: current perspectives. J Blood Med. 2016;7:217–25. DOI: 10.2147/JBM. S90693.
8. Neerman-Arbez M., de Moerloose P., Casini A. Laboratory and genetic investigation of mutations accounting for congenital fibrinogen disorders. Semin Thromb Hemost. 2016;42(4):356–65. DOI: 10.1055/s-0036–1571340.
9. Ruiz-Saez A. Occurrence of thrombosis in rare bleeding disorders. Semin Thromb Hemost. 2017;39(6):684–92. DOI: 10.1055/s-0033– 1353391.
10. Vasse M., Francois D., Van Dreden P., de Mazancourt P. Different sensitivity of von Clauss reagents for the diagnosis of dysfibrinogenemia. Eur J Haematol. 2020;104(1):70–71. DOI: 10.1111/ejh.13333.
11. Jiang L., Zhang Q., Xu W., Zhang Y. Mutation analysis of a FGG gene causing hereditary abnormal fibrinogen. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2018;35(6):812–14. DOI: 10.3760/cma.j.i ssn.1003–9406.2018.06.008.